Workshop Report: Concepts and methods in the economics of nutrition - Gateways to better economic evaluation of nutrition interventions

British Journal of Nutrition

Volumn 108, Issue 9, 2012, Pages 1714-1720

  Lenoir Wijnkoop, I ^a   Nuijten, M J C ^b   Gutierrez Ibarluzea I ^c,d   Hutton, J ^e   Poley, M J ^f   Segal, L ^g   Bresson, J L ^h   Van Ganse, E ⁱ   Jones, P ^j   Moreno, L ^k   Salminen, S ^l   Dubois, D ^m  

^a DANONE RESEARCH   (France)

^b Ars Accessus Medica   (Netherlands)

^c Osteba   (Spain)

^d Osakidetza   (Spain)

^e UNIVERSITY OF YORK   (United Kingdom)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

^j UNIVERSITY OF MANITOBA   (Canada)

^k UNIVERSITY OF ZARAGOZA   (Spain)

^l UNIVERSITY OF TURKU   (Finland)

^m UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

more..

Author keywords

Cost effectiveness; Health technology assessment; Nutrition economics; Preventive interventions; Public health guidance

Indexed keywords

CHRONIC DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROMOTION; HIGH RISK POPULATION; MEDICAL DECISION MAKING; NUTRITION ECONOMICS; NUTRITIONAL HEALTH; OUTCOME ASSESSMENT; PUBLIC HEALTH SERVICE; QUALITY OF LIFE;

BIOMEDICAL TECHNOLOGY; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; DIET; EVIDENCE-BASED MEDICINE; HUMANS; NUTRITION DISORDERS; NUTRITION POLICY;

EID: 84870015709     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512003704     Document Type: Conference Paper

References (55)

1. Park M, Braun T & Carrin G (2007) Technical Briefs for Policymakers. WHO Department of Health Systems Financing No. 2. Geneva: World Health Organization.
2. Ginsburg PB (2004) Controlling health care costs. N Engl J Med 351, 1591-1593.
3. World Health Organization & European Observatory on Health Systems and Policies Series (2005) Purchasing to Improve Health Systems Performance [J Figueras, R Robinson and E Jakubowski, editors]. Milton Keynes: Open University Press.
4. Drummond MF, Dubois D, Garattini L, et al. (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2, 323-332.
5. Lenoir-Wijnkoop I, Dapoigny M, Dubois D, et al. (2011) Nutrition economics: characterising the economic and health impact of nutrition. Br J Nutr 105, 157-166.
6. Fayers P & Bottomley A (2002) Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer 38, S125-S133.
7. Leidy NK, Revicki DA & Genesté B (1999) Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 2, 113-127.
8. FDA Guidance for Industry (2009) Patient-reported outcome measures: use in medical product development to support labeling claims. www.fda.gov/ downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/UCM193282. pdf.
9. Drummond M, Brixner D, Gold M, et al. (2009) Toward a consensus on the QALY. Value Health 12, S31-S35.
10. Cambridge, Harvard School of Public Health (1996) The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 [CJL Murray and AD Lopez, editors]. Cambridge, MA: Harvard School of Public Health.
11. Torrance GW, Furlong W, Feeny D, et al. (1995) Multiattribute preference functions. Health Utilities Index. Pharma-coeconomics 7, 503-520.
12. Arnesen T & Trommald M (2005) Are QALYs based on time trade-off comparable? A systematic review of TTO methodologies. Health Econ 14, 39-53.
13. The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16, 199-208.
14. Richardson J, Iezzi A, Sihna K, et al. (2009) AQoL-7D (Vision) Instrument: Overview, survey results and utility algorithms. Monash University, Research Paper 2009 (45).
15. World Bank & World Development Report (1993) Investing in Health. New York: Oxford University Press.
16. Soares MO (2012) Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity. Br Med Bull 101, 17-31.
17. Muldoon MF, Barger SD, Flory JD, et al. (1998) What are quality of life measurements measuring? Br Med J 316, 542-545.
18. Slevin ML, Plant H, Lynch D, et al. (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57, 109-112.
19. Measurement in clinical trials: review and qualification of clinical outcome assessments, Public Workshop October 2011, White Oak, MD. http://www.fda.gov/Drugs/NewsEvents/ucm276110.htm
20. Fried TR, Tinetti ME, Towle V, et al. (2011) Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 171, 923-928.
21. Fidler C, Christensen TE & Gillard S (2011) Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 14, 646-655.
22. Nnoaham KE, Sacks G, Rayner M, et al. (2009) Modelling income group differences in the health and economic impacts of targeted food taxes and subsidies. Int J Epidemiol 38, 1324-1333.
23. Duffey KJ, Gordon-Larsen P, Shikany JM, et al. (2010) Food price and diet and health outcomes:20 years of The CARDIA Study. Arch Intern Med 5, 420-426.
24. Observatory on Health Systems and Policies (2006) Health in All Policies-Prospects and Potentials [T Ståhl, M Wismar and E Ollila, et al., editors]. http://ec.europa.eu/health/archive/ph-information/documents/health- in-all-policies. pdf
25. Ståhl T (2010) Is health recognised in the EU's policy process? An analysis of the European Commission's impact assessments. Eur J Public Health 2, 176-181.
26. Ubel PA, Baron J, Nash B, et al. (2002) Are preferences for equity over efficiency in health care allocation "all or nothing"? Med Care 38, 366-373.
27. NICE (2011) Supporting local investment in public health-using evidence on cost effectiveness, cost impact and return on investment to inform local commissioning. http://www.nice.org.uk/media/737/C5/CostImpactSynopsis.pdf
28. Graves N (2006) Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions. Chronic Illness 2, 97-107.
29. Lenoir-Wijnkoop I, van Aalderen WM, Boehm G, et al. (2012) Cost-effectiveness model for a specific mixture of pre-biotics in The Netherlands. Eur J Health Econ 13, 101-110.
30. Lötters FJB, Lenoir-Wijnkoop I, Fardellone P, et al. (2012) Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int (epublication ahead of print version 16 June 2012).
31. Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I, et al. (2012) Primary prevention of nephrolithiasis is cost-effective for a national health care system. Br J Urol (epublication ahead of print version 11 June 2012).
32. Puska P, Nissinen A & Tuomilehto J (1985) The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Ann Rev Public Health 6, 147-193.
33. Puska P (2009) Fat and heart disease: yes we can make a change-the case of North Karelia (Finland). Ann Nutr Metab 54, S33-S38.
34. Puska P & Ståhl T (2010) Health in all policies-the Finnish initiative: background, principles, and current issues. Annu Rev Public Health 31, 315-328.
35. Sesé MA, Jiménez-Pavón D, Gilbert CC, et al. (2012) Eating behaviour, insulin resistance and cluster of metabolic risk factors in European adolescents. The HELENA Study. Appetite 59, 140-147.
36. Health Canada. (2006) Canadian Community Health Survey, Cycle 2.2, Nutrition (2004)-A Guide to Accessing and Interpreting the Data. Ottawa, ON: Health Canada. http://www.hc-sc.gc.ca/fn-an/alt-formats/hpfb-dgpsa/pdf/surveill/ cchs-guide-escc-eng.pdf
37. Duffey KJ, Steffen LM, Van Horn L, et al. (2012) Dietary patterns matter: diet beverages and cardiometabolic risks in the longitudinal Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr 95, 909-915.
38. Buckland G, Agudo A, Luja'n L, et al. (2010) Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr 91, 381-390.
39. Blumfield M, Hure A, MacDonald-Wicks L, et al. (2011) Disparities exist between national food group recommendations and the dietary intakes of women. BMC Women's Health 11, 37.
40. Upshur REG (2003) Are all evidence-based practices alike? Problems in the ranking of evidence. CMAJ 169, 672-673.
41. Tonelli MR (2001) The limits of evidence-based medicine. Resp Care 46, 1435-1440.
42. Rothwell PM (2005) External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 365, 82-93.
43. Ioannidis JPA (2008) Some main problems eroding the credibility and relevance of randomized trials. Bull NYU Hosp Joint Dis 66, 135-139.
44. Guyatt GH, Oxman AD, Kunz R, et al. (2008) Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? BMJ 336, 995-998.
45. Rawlins M (2008). De Testimonio: on the evidence for decisions about the use of therapeutic interventions. The Royal College of Physicians of London Harveian Oration. http://www.rcplondon.ac.uk/pubs/brochure.aspx?e/262
46. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328, 1490.
47. Ibargoyen-Roteta N, Gutierrez-Ibarluzea I, Rico-Iturrioz R, et al. (2010) The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 16, 48.
48. Nathan DM, Buse JB, Davidson MB, et al. (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963-1972.
49. American Diabetes Association (2008) Clinical practice recommendations. Standards of medical care in diabetes-2008. Diabetes Care 31, Suppl. 1, S12-S54.
50. Agence Française de Sécurité Sanitaire des Produits de Santé (2006) Traitement médicamenteux de l'ostéoporose post-ménopausique. Recommendations (Drug Treatment of Post-menopausal Osteoporosis. Recommendations). Saint-Denis: Agence Française de Sécurité Sanitaire des Produits de Santé.
51. Nuijten M, Renkens M, Kogels E, et al. (2011) The decision making process of payers: a pilot survey in The Netherlands. ISPOR Connections 8-9.
52. Plotnikoff GA (2003) Food as medicine-cost-effective health care? Minnesota Med 86, 41-45.
53. McCarron DA & Heaney RP (2004) Estimated healthcare savings associated with adequate dairy food intake. Am J Hypertens 17, 88-97.
54. Dalziel K & Segal L (2007) Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. Health Prom Int 22, 271-283.
55. Doidge JC, Gospodarevskaya E & Segal L (2011) 7th Health Services & Policy Research Conference, Adelaide, SA, Australia.